Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lars Bastholt

Showing results (111-120 of 134) with videos related to

Pageof 14
Sort By:
European Journal of Cancer (Oxford, England : 1990)|May 30, 2020
Adjuvant therapy with pegylated interferon-alfa2b vs observation in stage II B/C patients with ulcerated primary: Results of the European Organisation for Research and Treatment of Cancer 18081 randomised trialAlexander M M Eggermont, Piotr Rutkowski, Caroline Dutriaux, et al.
European Journal of Cancer (Oxford, England : 1990)|January 14, 2020
European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2019Claus Garbe, Teresa Amaral, Ketty Peris, et al.
Nature|April 3, 2020
Author Correction: Tertiary lymphoid structures improve immunotherapy and survival in melanomaRita Cabrita, Martin Lauss, Adriana Sanna, et al.
Nature|January 17, 2020
Tertiary lymphoid structures improve immunotherapy and survival in melanomaRita Cabrita, Martin Lauss, Adriana Sanna, et al.
European Journal of Cancer (Oxford, England : 1990)|December 24, 2019
European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2019Claus Garbe, Teresa Amaral, Ketty Peris, et al.
European Journal of Cancer (Oxford, England : 1990)|September 26, 2020
Response to: Comment on 'Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines'Ketty Peris, Maria C Fargnoli, Claus Garbe, et al.
European Journal of Cancer (Oxford, England : 1990)|April 4, 2020
Comment on 'Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines'Ketty Peris, Maria C Fargnoli, Claus Garbe, et al.
European Journal of Cancer (Oxford, England : 1990)|July 10, 2019
Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelinesKetty Peris, Maria Concetta Fargnoli, Claus Garbe, et al.
Journal for Immunotherapy of Cancer|June 7, 2020
Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanomaPaolo Antonio Ascierto, Michele Del Vecchio, Andrzej Mackiewicz, et al.
The Lancet. Oncology|April 1, 2017
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trialPaolo A Ascierto, Michele Del Vecchio, Caroline Robert, et al.
Pageof 14

Showing results (111-120 of 134) with videos related to

Sort By:
Pageof 14
European Journal of Cancer (Oxford, England : 1990)|May 30, 2020
Adjuvant therapy with pegylated interferon-alfa2b vs observation in stage II B/C patients with ulcerated primary: Results of the European Organisation for Research and Treatment of Cancer 18081 randomised trialAlexander M M Eggermont, Piotr Rutkowski, Caroline Dutriaux, et al.
European Journal of Cancer (Oxford, England : 1990)|January 14, 2020
European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2019Claus Garbe, Teresa Amaral, Ketty Peris, et al.
Nature|April 3, 2020
Author Correction: Tertiary lymphoid structures improve immunotherapy and survival in melanomaRita Cabrita, Martin Lauss, Adriana Sanna, et al.
Nature|January 17, 2020
Tertiary lymphoid structures improve immunotherapy and survival in melanomaRita Cabrita, Martin Lauss, Adriana Sanna, et al.
European Journal of Cancer (Oxford, England : 1990)|December 24, 2019
European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2019Claus Garbe, Teresa Amaral, Ketty Peris, et al.
European Journal of Cancer (Oxford, England : 1990)|September 26, 2020
Response to: Comment on 'Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines'Ketty Peris, Maria C Fargnoli, Claus Garbe, et al.
European Journal of Cancer (Oxford, England : 1990)|April 4, 2020
Comment on 'Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines'Ketty Peris, Maria C Fargnoli, Claus Garbe, et al.
European Journal of Cancer (Oxford, England : 1990)|July 10, 2019
Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelinesKetty Peris, Maria Concetta Fargnoli, Claus Garbe, et al.
Journal for Immunotherapy of Cancer|June 7, 2020
Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanomaPaolo Antonio Ascierto, Michele Del Vecchio, Andrzej Mackiewicz, et al.
The Lancet. Oncology|April 1, 2017
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trialPaolo A Ascierto, Michele Del Vecchio, Caroline Robert, et al.
Pageof 14